The Hi-Tech to Pharma Switch – Is it Feasible?
The Technology world has seen many entrepreneurs excel over the last several years. Some of them stand out for not only their achievements in that field, but also in their continuing spirit of entrepreneurship that takes them into different areas such as pharmaceuticals, biotechnology and related fields. Our panelists are two such individuals. They have started up pharma-related ventures after successful careers in completely unrelated fields.
Is the transition feasible? Is it easy? Is it desirable? Who could better answer these questions than someone who has lived through it all. Please join us for what promises to be an invigorating panel discussion.
Date: July 27, 2006
Place: HP Auditorium, 3000 Hanover Street, Palo Alto, CA 94304
Map Google | Yahoo | Mapquest
Agenda: Networking/refreshments: 6:30 pm
Presentations: 7:30 pm
Panel discussion: 8:00 pm
Adjourn: 9:00 pm
Co-Founder and Chairman, Wafergen
Mr Shivji has been a venture investor as a Partner with Global Asset Capital (a silicon valley based VC firm) and VPSA (a Paris based VC firm) since 2002. He is also the co-founder and Chairman of Wafergen, a biotech firm based in Fremont, California. He was President of CIENA, Metro Switching Division. Prior to that, he founded Cyras Systems and served as its President and CEO until it was acquired by CIENA for $2.6 billion in March 2001. He also co-founded Fiberlane Communications, which changed the face of the networking communications industry when it split into Cerent (acquired by Cisco for $7 billion) and Siara Systems (acquired by Redback Networks for $4.3 billion). Mr. Shivji also founded OSIware, a communications software company that was sold to Infonet, a value added service provider now part of British Telecom.
Mr. Shivji currently serves on the Boards of WaferGen, OneAccess, Silecs, Neophotonics and is a Charter member of several entrepreneurial organizations like TiE, ASVC and OPEN. He co-founded Wafergen with the vision of bringing hi-tech to benefit unmet needs in biotech. Wafergen is already proving that with its current products in the cell research and bioprocessing markets. Mr. Shivji also expects Wafergen to play a significant role in molecular diagnostics and personalized medicine.
Amit Goswamy, BS, MBA
President, CEO & Co-founder, Chakshu Research
Amit is an entrepreneur and senior business executive with over 20 years of experience in global business management and marketing. He is an MBA from Stanford Business School and a B.S. in Engineering from Indian Institute of Technology (IIT). Prior to co-founding Chakshu Research in 2002, Amit was the founding President and CEO of Spotlife Inc. SpotLife was a leader in starting the personal Internet video trend. The software and service was exclusively packaged with over 75% of the PC Cameras shipped worldwide. The company was acquired by Logitech, Inc. in 2002. Before SpotLife, Amit was the President & CEO of Mayasoft Corporation, one of the early enterprise application integration companies. E.piphany, Inc. acquired Mayasoft in 1999. Before Mayasoft, Amit was the General Manager for the Professional Electronic Products division at Eastman Kodak Company.
He co-founded Chakshu Research believing that the company could potentially revolutionize ophthalmology. He has lead Chakshu from a groundbreaking idea and theory, into a young company that is already attracting the attention of the leading ophthalmic researchers.
Anish Bhatnagar, MD
Please note that all attendees for this event will be offered free membership for the rest of the calendar year. Membership benefits include access to members-only networking events, database of contact information for other EPPIC members and the EPPIC newsletter. Membership can be obtained on-site at the event.